These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

833 related articles for article (PubMed ID: 33208445)

  • 41. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses.
    Metz SW; Tian S; Hoekstra G; Yi X; Stone M; Horvath K; Miley MJ; DeSimone J; Luft CJ; de Silva AM
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005071. PubMed ID: 27764114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature.
    Boigard H; Cimica V; Galarza JM
    Vaccine; 2018 Nov; 36(50):7728-7736. PubMed ID: 30377067
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.
    Khetarpal N; Shukla R; Rajpoot RK; Poddar A; Pal M; Swaminathan S; Arora U; Khanna N
    Am J Trop Med Hyg; 2017 Jan; 96(1):126-134. PubMed ID: 27821688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
    Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
    Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dengue Mosaic Vaccines Enhance Cellular Immunity and Expand the Breadth of Neutralizing Antibody Against All Four Serotypes of Dengue Viruses in Mice.
    Hou J; Shrivastava S; Fraser CC; Loo HL; Wong LH; Ho V; Fink K; Ooi EE; Chen J
    Front Immunol; 2019; 10():1429. PubMed ID: 31281322
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neutralizing and enhancing antibody responses to five genotypes of dengue virus type 1 (DENV-1) in DENV-1 patients.
    Yamanaka A; Moi ML; Takasaki T; Kurane I; Konishi E
    J Gen Virol; 2017 Feb; 98(2):166-172. PubMed ID: 27911254
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.
    Metz SW; Thomas A; Brackbill A; Xianwen Y; Stone M; Horvath K; Miley MJ; Luft C; DeSimone JM; Tian S; de Silva AM
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006793. PubMed ID: 30248097
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
    Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
    J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-Term Protection Elicited by a DNA Vaccine Candidate Expressing the prM-E Antigen of Dengue Virus Serotype 3 in Mice.
    Feng K; Zheng X; Wang R; Gao N; Fan D; Sheng Z; Zhou H; Chen H; An J
    Front Cell Infect Microbiol; 2020; 10():87. PubMed ID: 32257963
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genotype-specific and cross-reactive neutralizing antibodies induced by dengue virus infection: detection of antibodies with different levels of neutralizing activities against homologous and heterologous genotypes of dengue virus type 2 in common marmosets (Callithrix jacchus).
    Azami NAM; Moi ML; Ami Y; Suzaki Y; Lim CK; Taniguchi S; Saijo M; Takasaki T; Kurane I
    Virol J; 2018 Mar; 15(1):51. PubMed ID: 29587780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans.
    Nivarthi UK; Swanstrom J; Delacruz MJ; Patel B; Durbin AP; Whitehead SS; Kirkpatrick BD; Pierce KK; Diehl SA; Katzelnick L; Baric RS; de Silva AM
    Nat Commun; 2021 Feb; 12(1):1102. PubMed ID: 33597521
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.
    Smith SA; de Alwis AR; Kose N; Harris E; Ibarra KD; Kahle KM; Pfaff JM; Xiang X; Doranz BJ; de Silva AM; Austin SK; Sukupolvi-Petty S; Diamond MS; Crowe JE
    mBio; 2013 Nov; 4(6):e00873-13. PubMed ID: 24255124
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice.
    Zuest R; Valdes I; Skibinski D; Lin Y; Toh YX; Chan K; Hermida L; Connolly J; Guillen G; Fink K
    Vaccine; 2015 Mar; 33(12):1474-82. PubMed ID: 25659270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines.
    Borges MB; Marchevsky RS; Carvalho Pereira R; da Silva Mendes Y; Almeida Mendes LG; Diniz-Mendes L; Cruz MA; Tahmaoui O; Baudart S; Freire M; Homma A; Schneider-Ohrum K; Vaughn DW; Vanloubbeeck Y; Lorin C; Malice MP; Caride E; Warter L
    PLoS Pathog; 2019 Apr; 15(4):e1007721. PubMed ID: 31009499
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.
    Elong Ngono A; Shresta S
    Front Immunol; 2019; 10():1316. PubMed ID: 31244855
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
    Henein S; Swanstrom J; Byers AM; Moser JM; Shaik SF; Bonaparte M; Jackson N; Guy B; Baric R; de Silva AM
    J Infect Dis; 2017 Feb; 215(3):351-358. PubMed ID: 27932620
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
    Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.